Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Not As Easy' OTC Codeine Label Changes Worry FDA Rx Product Advisors

Executive Summary

FDA officials acknowledge at the Pediatric Advisory Committee Sept. 11 that labeling restrictions for opioid-containing Rx antitussives for pediatric cough wouldn't apply to labeling for codeine cough products available under an OTC monograph.


Related Content

Legislators On OTC Monograph Reform: What Took You So Long?
Opioid Cough Restrictions: Pediatric Use, And Postmarket Studies, Likely Limited
Opioids: FDA Eyes Better Prescriber Education, But Academics Urge Promotion Crackdown
“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts